U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177703) titled 'Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension' on Sept. 10.
Brief Summary: Pulmonary Arterial Hypertension (PAH) is a serious condition that puts strain on the right side of the heart. While oral medications can help, many patients with intermediate-risk PAH may not see enough improvement, and their heart function can continue to decline.
This study aims to find out if adding an injectable medication, Treprostinil, to a patient's current oral PAH therapy can improve heart function and overall health. This is a single-arm study, which means all participants will receive the study treatment...